PMID: 3100314Jan 1, 1986Paper

Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide

European Journal of Clinical Pharmacology
J B ChalkM J Eadie


A study has been carried out investigating four different marketed oral preparations of glibenclamide, correlating the effectiveness of the drug in these preparations in lowering plasma glucose concentrations with the in vitro dissolution of the drug, measured by the British Pharmacopoeal and Desaga methods, and the in vivo bioavailability, assessed in 12 healthy human volunteers. The two dissolution methods yielded different rank orders of ease of dissolution of the drug from the various preparations; the findings of neither dissolution method correlated adequately with the results of the in vivo bioavailability studies, which correctly predicted the abilities of the preparations to reduce plasma glucose concentrations. Relative to an oral glibenclamide solution the bioavailabilities of the drug from three tablet preparations were 0.69, 0.49 and 0.24. The mean elimination half-life of the drug was 1.5 h and assuming complete bioavailability of the drug from oral solution the mean systemic clearance was 0.095 l kg-1h-1, and the mean apparent volume of distribution was 0.20 l kg-1. It is concluded that it may be unsafe to use in vitro dissolution data as a basis for assessing the bioequivalences of different glibenclamide prepar...Continue Reading


Jan 1, 1975·European Journal of Clinical Pharmacology·L BalantG R Zahnd
Feb 1, 1973·The Journal of Clinical Pharmacology and New Drugs·L M FuccellaG Valzelli


Jul 28, 2011·Wiener medizinische Wochenschrift·B RocićMarijana Vučić Lovrenčić
Feb 17, 2000·International Journal of Pharmaceutics·A Panagopoulou-Kaplani, S Malamataris
Jun 1, 1990·British Journal of Clinical Pharmacology·S W CoppackA V Rodgers
Aug 1, 1991·British Journal of Clinical Pharmacology·P J Neuvonen, K T Kivistö
Nov 1, 1994·British Journal of Clinical Pharmacology·W D ByromJ R Bratty
Apr 22, 2009·AAPS PharmSciTech·Yogeshwar G Bachhav, Vandana B Patravale
Jun 22, 2000·Analytical Biochemistry·F MagniM Galli Kienle
Nov 27, 2010·Pharmaceutical Development and Technology·Paola MuraNatascia Mennini
Feb 27, 2014·Drug Development and Industrial Pharmacy·Heba F Mansour, Usama F Aly
Dec 22, 1999·Drug Development and Industrial Pharmacy·R J Babu, J K Pandit
Dec 10, 2015·AAPS PharmSciTech·Roberta CensiPiera Di Martino
Sep 3, 2009·Biotechnology and Bioengineering·Ece Dilber GamsizRebecca Lyn Carrier
Jun 1, 1989·Journal of Clinical Pharmacy and Therapeutics·M E Abdel-HamidM M Hasan
Nov 5, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Jibin GuanTianhong Zhang
Apr 20, 2016·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Marzia CirriPaola Mura
Apr 26, 2017·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rui LiManthena V S Varma

Related Concepts

Blood Glucose
Total Body Clearance Rate

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.